Agerafenib

Chemical compound From Wikipedia, the free encyclopedia

Agerafenib is a selective multi-kinase inhibitor. It is undergoing a trial to test its ability to treat malignant tumors in humans. It is effective in doses ranging between 30 milligrams and 100 milligrams. It is also known as CEP-32496 and RXDX 105. It is a strong inhibitor of the BRAF gene, which is commonly found in cancerous cells.

Quick facts Names, Identifiers ...
Agerafenib
Names
IUPAC name
1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea
Other names
  • CEP-32496
  • AC013773
  • Rxdx 105
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)
    Key: DKNUPRMJNUQNHR-UHFFFAOYSA-N
  • CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F
Properties
C24H22F3N5O5
Molar mass 517.465 g·mol−1
Solubility ≥ 25.85 mg/mL in DMSO
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Close

Discovery

Agerafenib was originally discovered by a company called Daiichi Sankyo (then called Ambit Biosciences) and Teva Pharmaceuticals (then called Cephalon) during a research program.[1] The chemical was originally named "CEP-32496" before being renamed to "RXDX 105" in 2015.[1] It is currently undergoing a clinical trial to test its effectiveness against cancer in humans.[2]

Characteristics

Agerafenib's chemical formula consists of 24 carbon atoms, 22 hydrogen atoms, 3 fluorine atoms, 5 nitrogen atoms and 5 oxygen atoms.[3] The chemical's molar mass is 517.465 g/mol, and the monoisotopic mass is 517.157303 g/mol.[4] It appears as a white to off-white crystalline powder in room temperature.[5] Agerafenib has 5 hydrogen bond acceptors and 2 hydrogen bond donors.[6] It has an partition coefficient of 4.35. It has 10 rotatable bonds and a topological polar surface area of 120.63.[6]

The chemical is a strong inhibitor of the BRAF gene, which is present in around 7% of all malignant tumors.[7] It does this due to its strong cytotoxicity to cells containing it.[7] Agerafenib also inhibits phosphorylation in mitogen-activated protein kinase (an enzyme that causes certain cellular responses).[8] The drug is shown to be most effective in humans in doses between 30 milligrams and 100 milligrams.[9]

References

Related Articles

Wikiwand AI